SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-004488 to Neptune Wellness Solutions Inc. (NEPTF) (CIK 0001401395)

Neptune Wellness Solutions Inc. (NEPTF) (CIK 0001401395)
Date: May 1, 2023 · CIK: 0001401395 · Accession: 0000000000-23-004488

AI Filing Summary & Sentiment

File numbers found in text: 333-271403

Date
May 1, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Neptune Wellness Solutions Inc. (NEPTF) (CIK 0001401395)

Letter

United States securities and exchange commission logo May 1, 2023 Raymond Silcock Chief Financial Officer Neptune Wellness Solutions Inc. 28 Liberty Street New York, NY 10005 Re:Neptune Wellness Solutions Inc. Registration Statement on Form S-1 Filed April 24, 2023 File No. 333-271403 Dear Raymond Silcock: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas Rose, Esq.

Show Raw Text
United States securities and exchange commission logo
May 1, 2023
Raymond Silcock
Chief Financial Officer
Neptune Wellness Solutions Inc.
28 Liberty Street
New York, NY 10005
Re:Neptune Wellness Solutions Inc.
Registration Statement on Form S-1
Filed April 24, 2023
File No. 333-271403
Dear Raymond Silcock:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Thomas Rose, Esq.